153 related articles for article (PubMed ID: 29980576)
1. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry.
Bergstra SA; Branco JC; Vega-Morales D; Salomon-Escoto K; Govind N; Allaart CF; Landewé RBM
Ann Rheum Dis; 2018 Oct; 77(10):1413-1420. PubMed ID: 29980576
[TBL] [Abstract][Full Text] [Related]
2. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?
Putrik P; Ramiro S; Kvien TK; Sokka T; Uhlig T; Boonen A;
Ann Rheum Dis; 2014 Nov; 73(11):2010-21. PubMed ID: 23940213
[TBL] [Abstract][Full Text] [Related]
3. Inequities in access to biologic and synthetic DMARDs across 46 European countries.
Putrik P; Ramiro S; Kvien TK; Sokka T; Pavlova M; Uhlig T; Boonen A;
Ann Rheum Dis; 2014 Jan; 73(1):198-206. PubMed ID: 23467636
[TBL] [Abstract][Full Text] [Related]
4. Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study.
Nikiphorou E; van der Heijde D; Norton S; Landewé RB; Molto A; Dougados M; Van den Bosch FE; Ramiro S
Ann Rheum Dis; 2018 Mar; 77(3):405-411. PubMed ID: 29222349
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.
Gabay C; Riek M; Scherer A; Finckh A;
Rheumatology (Oxford); 2015 Sep; 54(9):1664-72. PubMed ID: 25922549
[TBL] [Abstract][Full Text] [Related]
6. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE
PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971
[TBL] [Abstract][Full Text] [Related]
7. Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries.
Glintborg B; Lindström U; Aaltonen K; Kristianslund EK; Gudbjornsson B; Chatzidionysiou K; Askling J; Nordström D; Hetland ML; Di Giuseppe D; Dreyer L; Kristensen LE; Jørgensen TS; Eklund K; Grondal G; Ernestam S; Joensuu J; Törmänen M; Skydsgaard H; Hagfors J; Kvien TK; Lie E; Fagerli K; Geirsson AJ; Jonsson H; Provan SA; Krogh NS; Jacobsson L
Scand J Rheumatol; 2018 Nov; 47(6):465-474. PubMed ID: 30070923
[TBL] [Abstract][Full Text] [Related]
8. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
[TBL] [Abstract][Full Text] [Related]
9. [The first biologic for rheumatoid arthritis: factors influencing the therapeutic decision].
Pattloch D; Richter A; Manger B; Dockhorn R; Meier L; Tony HP; Zink A; Strangfeld A
Z Rheumatol; 2017 Apr; 76(3):210-218. PubMed ID: 27518855
[TBL] [Abstract][Full Text] [Related]
10. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
12. Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD.
Putrik P; Ramiro S; Lie E; Keszei AP; Kvien TK; van der Heijde D; Landewé R; Uhlig T; Boonen A
Rheumatology (Oxford); 2016 Jul; 55(7):1217-24. PubMed ID: 27012686
[TBL] [Abstract][Full Text] [Related]
13. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
14. Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD.
Espinoza F; Le Blay P; Combe B
J Rheumatol; 2017 Jun; 44(6):844-849. PubMed ID: 28412711
[TBL] [Abstract][Full Text] [Related]
15. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis.
Wilke T; Mueller S; Lee SC; Majer I; Heisen M
BMC Musculoskelet Disord; 2017 Aug; 18(1):332. PubMed ID: 28764705
[TBL] [Abstract][Full Text] [Related]
16. Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.
Kalkan A; Husberg M; Hallert E; Roback K; Thyberg I; Skogh T; Carlsson P
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1679-85. PubMed ID: 26097219
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan.
Tanaka E; Inoue E; Yamaguchi R; Shimizu Y; Kobayashi A; Sugimoto N; Hoshi D; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
Mod Rheumatol; 2017 Mar; 27(2):227-236. PubMed ID: 27472516
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.
Gerhold K; Richter A; Schneider M; Bergerhausen HJ; Demary W; Liebhaber A; Listing J; Zink A; Strangfeld A
Rheumatology (Oxford); 2015 Oct; 54(10):1858-66. PubMed ID: 26001633
[TBL] [Abstract][Full Text] [Related]
19. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R
Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
